A Clinical Phase II Study of the Materna Device to Shorten Delivery Time During Childbirth

November 18, 2024 updated by: Materna Medical
This feasibility study is a prospective, non-randomized, single arm study to evaluate safety and prevention of maternal pelvic soft-tissue damage using the Materna Medical Device. The device will be used during the first stage of labor, following initiation of epidural anesthesia and after the cervix has dilated to between 3-8 cm. Up to 20 subjects will be included in the initial study, with the option to increase the number of subjects to 50 based on early data.

Study Overview

Status

Withdrawn

Conditions

Detailed Description

Study Inclusion Criteria are:

  1. Patients attending for antenatal care at El Camino Hospital with the Altos Oaks Obstetrics Group
  2. First ongoing pregnancy beyond 20 weeks
  3. Singleton, cephalic presentation
  4. No pregnancy complications which are likely to require Caesarean Section
  5. Planned vaginal delivery

The primary outcome measure is device safety as defined by freedom of device related adverse events. Secondary efficacy outcome measures are:

  1. Pelvic muscle damage as determined by ultrasound imaging
  2. Length of the 2nd stage of labour
  3. Delivery mode
  4. Perineal and anal sphincter trauma
  5. Symptoms of incontinence, prolapse and sexual dysfunction 2 years postpartum
  6. Pelvic organ support (ICS POP-Q system) and pelvic organ descent on ultrasound

Interested patients will have the study presented to them during their pre-natal visits with the Altos Oaks Obstetrics group. Interested patients will have the study explained to them and will be given the Informed Consent document.After the informed consent procedure, patients will undergo an interview and 4D translabial ultrasound.

The screened patients will have the Materna device administered by a researcher from the Altos Oaks Obstetrics group. The patients will be flagged in their charts regarding their participation in this study. When an enrolled patient arrives at the hospital and is deemed to be in labor, the Altos Oaks physician on call will be notified, and called to administer the use of the device. All other obstetric services are provided by routine staff. The device will be dilated up to a maximum diameter of 8-10cm and is then removed to allow delivery. The Control arm patients will experience normal care during labor. Participants are followed up at 3 months and 1 year after childbirth with an interview, including validated questionnaires on bladder, bowel and sexual function, and repeat ultrasound. Delivery details will be collected by the midwives and through the institutional database.

The study's primary efficacy outcome measure is levator avulsion injury diagnosed on volume ultrasound data obtained at the 1-3 month follow-up appointment. Secondary outcomes include both objective findings related to pelvic floor function and anatomy, as well as symptoms of pelvic floor dysfunction such as pelvic organ prolapse, urinary / fecal incontinence and dyspareunia, as ascertained by interview and questionnaire, at 3 months after childbirth. Assessment of stored ultrasound volume data (obtained on pelvic floor muscle contraction, or, if that is not possible, at rest) is undertaken at a later date by one single operator within the Altos Oaks Obstetrics group.

Study Type

Interventional

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • California
      • Mountain View, California, United States, 94040
        • El Camino Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  1. Primiparas, or previous pregnancy terminated before 24 weeks gestation
  2. Single fetus birth
  3. Subject is able to understand the risks and potential benefits of participating in the study and is willing to provide written informed consent.
  4. Subject is willing and able to comply with specified follow-up evaluations.
  5. Planned to have epidural during birthing process

Exclusion Criteria:

  1. Previous delivery, or previous pregnancy beyond 24 weeks gestation
  2. Less than 36 weeks gestation
  3. Neurological diseases e.g. Multiple Sclerosis that may result in unrelated pelvic disorders
  4. Muscular or skin disorder that affects elasticity of tissue such as scleroderma or lupus.
  5. Local or systemic infection e.g. HIV, herpes
  6. Any prior surgical procedures to the vaginal anatomy that could lead to pelvic dysfunction, pelvic fractures, or pelvic soft tissue injuries. Evaluated during baseline screening
  7. High likelihood of less than 1 hour of potential device dilation time after the woman arrives at the center and receives epidural

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Sham Comparator: Sham Control
Sham Control
Experimental: Materna Prep Device
Materna Prep Device

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Safety
Time Frame: 3 months post-delivery follow-up
Freedom from device related adverse events
3 months post-delivery follow-up

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Pelvic Muscle Avulsion
Time Frame: 1-3 months post delivery
Binary, determined with ultrasound imaging
1-3 months post delivery
Pelvic Muscle Damage
Time Frame: 1-3 Months Post-Delivery
Measured by changes in levator hiatus area, determined with ultrasound imaging
1-3 Months Post-Delivery
Delivery Time
Time Frame: Immediate after delivery
Measure the length of the second phase of labor
Immediate after delivery
Perineal Lacerations
Time Frame: Immediate Post Delivery
Record the grade of perineal lacerations, and if sutures were used to repair lacerations
Immediate Post Delivery
Instrument Deliveries
Time Frame: Immediate Post-Delivery
Record if instruments were used for delivery
Immediate Post-Delivery

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Principal Investigator: Kenneth Weber, MD, Obstatrician, Altos Oaks Medical Group

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

September 1, 2014

Primary Completion (Actual)

December 1, 2014

Study Completion (Actual)

December 1, 2014

Study Registration Dates

First Submitted

March 14, 2016

First Submitted That Met QC Criteria

November 18, 2024

First Posted (Estimated)

November 20, 2024

Study Record Updates

Last Update Posted (Estimated)

November 20, 2024

Last Update Submitted That Met QC Criteria

November 18, 2024

Last Verified

November 1, 2024

More Information

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Childbirth

Clinical Trials on Materna Prep Device

Subscribe